Silexion Therapeutics Ltd.SLXNNASDAQ
Loading
R&D Expense Growth Recovery in ProgressRecovering
Percentile Rank84
Year-over-Year Change
Year-over-year research & development expense growth
Latest
111.89%
↓ 97% vs avg
Percentile
P84
Within normal range
Streak
1 qtr
Consecutive growthRecovering
Average
3401.69%
Historical baseline
| Period | Value |
|---|---|
| Q3 2025 | 111.89% |
| Q2 2025 | 72.54% |
| Q1 2025 | 67638.23% |
| Q4 2024 | -99.97% |
| Q3 2024 | 319.97% |
| Q2 2024 | -20.29% |
| Q1 2024 | -23.55% |
| Q4 2023 | 134.95% |
| Q3 2023 | 0.00% |
| Q2 2023 | -100.00% |
| Q1 2023 | 0.00% |
| Q4 2022 | 0.00% |
| Q3 2022 | 0.00% |
| Q2 2022 | 0.00% |
| Q1 2022 | 0.00% |
| Q4 2021 | 0.00% |
| Q3 2021 | 0.00% |
| Q2 2021 | 0.00% |
| Q1 2021 | 0.00% |
| Q4 2020 | 0.00% |